Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 680 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vaccine 2 Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season

NCT03158038
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Monovalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

NCT03579459
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile vaccine, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
1,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
24
States / cities
Mobile, Alabama • Redding, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 17, 2026, 10:07 PM EDT
Active, not recruiting Phase 1 Interventional

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

NCT05743881
View directory record Official record
Conditions
Respiratory Syncytial Virus, Human Metapneumovirus
Interventions
mRNA-1345, mRNA-1365, Placebo, Nimenrix
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
5 Months to 24 Months
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

NCT05169905
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT vaccine, dTpa vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Beaumont, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

HPV Vaccine Communication ECHO for Primary Care Clinics

NCT04587167
View directory record Official record
Conditions
Human Papillomavirus Vaccines, Adolescent Health Services
Interventions
Project ECHO, Announcement Approach Training, Recall notices
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 1 Interventional

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo
Drug · Biological · Other
Lead sponsor
Donald T. Weed, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 17, 2026, 10:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

NCT06686654
View directory record Official record
Conditions
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Interventions
Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent), Licensed RSV Vaccine, Placebo, Investigational RSV+hMPV vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
1,530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Garden Grove, California • Gardena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

NCT04796896
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo, mRNA-1273.214
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Months to 11 Years
Enrollment
11,942 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ACE527 Safety and Immunogenicity Study

NCT00901654
View directory record Official record
Conditions
Enterotoxigenic E. Coli (ETEC) Infection
Interventions
ACE527 vaccine, Placebo vaccine
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2010 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

NCT03731182
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Wilmington, Delaware • Atlanta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 17, 2026, 10:07 PM EDT
Not yet recruiting Phase 2 Interventional

Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

NCT07390968
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration
Biological · Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 + TIV - Adults and Elderly

NCT00943878
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

NCT05464420
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
V116, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
2,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
30
States / cities
Mesa, Arizona • Tempe, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

NCT02839330
View directory record Official record
Conditions
Avian Influenza
Interventions
aH5N1c, Placebo
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
26
States / cities
Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 17, 2026, 10:07 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Melatonin and Vaccine Response, Immunity, and Chronobiology Study

NCT04953754
View directory record Official record
Conditions
Vaccine Response, Sleep, Circadian Rhythm Disorders
Interventions
Melatonin, Phillips Actiwatch Spectrum Plus
Dietary Supplement · Device
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Not applicable Interventional

HPV IIS Reminder/Recall- New York State

NCT03057379
View directory record Official record
Conditions
Reminder Systems
Interventions
Vaccine Reminder Recall
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
30,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults

NCT01157897
View directory record Official record
Conditions
Malaria, Plasmodium Vivax
Interventions
VMP001, P. vivax sporozoite challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

AFIX to Improve HPV Vaccination

NCT02370459
View directory record Official record
Conditions
Papillomavirus Vaccines, Adolescent Health Services
Interventions
AFIX in-person consultation, AFIX webinar consultation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Springfield, Illinois • Lansing, Michigan • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 2 Interventional

Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients

NCT00219362
View directory record Official record
Conditions
HIV Infection
Interventions
one injection of vCP1452 at W0, W4, W8 and W20, one injection of vCP1452 at W4, W8 and W20, one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20
Biological
Lead sponsor
Objectif Recherche Vaccins SIDA
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 1 Interventional

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

NCT01008527
View directory record Official record
Conditions
Melanoma
Interventions
CP 870,893, Peptides, Oncovir poly IC:LC
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 17, 2026, 10:07 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

NCT00282581
View directory record Official record
Conditions
HIV Infections, Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

NCT00373958
View directory record Official record
Conditions
Vaccines, Pneumococcal
Interventions
13 valent pneumococcal conjugate vaccine, 7vPnc pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
666 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
37
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 1 Interventional

Immunochemoradiotherapy in Patients With Pancreatic Cancer

NCT01342224
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
tadalafil and vaccination
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 17, 2026, 10:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

NCT01571960
View directory record Official record
Conditions
HIV Infections
Interventions
GEO-D03 DNA vaccine, MVA/HIV62B (MVA62B) vaccine, Placebo for GEO-D03 DNA, Placebo for MVA62B:
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 17, 2026, 10:07 PM EDT